You can also add to your health journal encourading news about advances in the rheumatoid arthritis management. Here are some of them:
Abatacept reduces the risk of developing rheumatoid arthritis
Scientists from the Hospital Clínic de Barcelona in 2026 presented data from a clinical trial comparing the effects of two drugs for preventing the development of rheumatoid arthritis in high-risk patients. Hydroxychloroquine, the gold standard of therapy, was more than twice as effective as abatacept, a drug currently used to treat autoimmune diseases. The study involved 70 patients with palindromic rheumatism, an autoimmune disease characterized by attacks of joint inflammation. Approximately half of these patients eventually develop rheumatoid arthritis, which causes irreversible joint damage. Hydroxychloroquine remains the standard treatment for palindromic rheumatism; this drug has anti-inflammatory and immunomodulatory effects and is used to control symptoms.
Hydrogel for osteoarthritis treatment developed in China
A team of scientists from Northwest University in China in 2025 developed a hydrogel for cartilage restoration in osteoarthritis. It reduces tissue inflammation and provides a favorable environment for natural repair. The gradual restoration is achieved through the slow release of drugs: first, anti-inflammatory agents act, followed by the slow penetration of compounds that stimulate mesenchymal stem cells to differentiate into chondrocytes and support their function over the long term. Experiments on rabbit models demonstrated complete restoration of cartilage tissue defects. The scientists are now refining the hydrogel for future testing in clinical trials. In addition to cartilage restoration, they plan to adapt the technology for the regeneration of tendon and bone defects.
New way to block inflammation from rheumatoid arthritis found
One of the most important discoveries in the field of rheumatoid arthritis in the last few decades was the discovery of the TNF-alpha protein, which plays a crucial role in joint inflammation. Following this discovery, drugs that inhibit this protein were developed. However, they do not work for everyone, and for some, they cause side effects. A group of researchers at the Washington School of Medicine led by Salah-Uddin Ahmed in 2022 found a new, even more promising target – sulfatase-2. Experiments with inhibiting this protein showed a significant reduction in inflammatory responses in cells. Although these are still preclinical trials, a sulfatase-2 inhibitor is already undergoing Phase II human clinical trials as a treatment for severe forms of brain cancer. Therefore, if this mechanism is further confirmed in rheumatoid arthritis, testing may begin at an accelerated pace.
AI system determines the type of arthritis
There are many types of joint inflammation, and accurately identifying them is difficult even for an experienced physician, which directly impacts the quality of medical care. A group of researchers from the University Hospital Erlangen in Germany developed and trained an AI model that can accurately differentiate between rheumatoid arthritis, psoriatic arthritis, and healthy joints based on X-ray images. The AI analyzed 932 images from 611 previously diagnosed patients. It recognized healthy joints with 82% accuracy, identifying 75% of rheumatoid arthritis cases and 68% of psoriatic arthritis cases. These are very high figures without any other additional information, the authors emphasized, and when combined with the experience of a rheumatologist, the results can lead to accurate diagnoses in a short period of time.
Pfizer/Eli Lilly osteoarthritis drug works, but safety concerns remain
It appears that the promising osteoarthritis painkiller Tanezumab, which was supposed to replace opioids for pain relief, will not be approved after all. Two pharmaceutical giants – Pfizer and Eli Lilly (in 2021) failed to obtain FDA approval for its use. This is despite the drug having been under development for 15 years, and having completed Phase 3 clinical trials two years ago. The drug is a monoclonal antibody that inhibits nerve growth factor in the joint. The FDA reviewed the latest data and stated that there is no doubt about the drug's effectiveness, but they are concerned about the risk of developing rapidly progressive osteoarthritis (RPOA) in some patients. And although the FDA hasn't yet issued a definitive NO, it appears the companies are ready to throw in the towel.